VivoSeq
Other

Opioid

0

Pipeline Programs↗

17

Active Trials↗

5

Companies Involved↗

Opioid is an early-stage landscape with 0 programs across 5 companies. The most active players are Daisy Pharma Opioid Venture, LLC, Heron Therapeutics, Braeburn Pharmaceuticals.

Intelligence

Pipeline Metrics

Competitive Density

34/100

Pipeline Velocity

11/100

Mech. Concentration

N/A

Completion Rate

81/100

Attrition Rate

13/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

D

Daisy Pharma Opioid Venture, LLC

0 programs

PreclinicalH

Heron Therapeutics

0 programs

PreclinicalB

Braeburn Pharmaceuticals

0 programs

PreclinicalPfizer logo

Pfizer

0 programs

PreclinicalC

Cerevel Therapeutics, LLC

0 programs

Preclinical

Pipeline

Programs by Phase

No pipeline programs currently tracked for this disease.

Analysis

Trial Status

67

clinical trials

Completed38 · 57%
Recruiting9 · 13%
Terminated8 · 12%
Unknown status3 · 4%
Enrolling by invitation3 · 4%
Not yet recruiting3 · 4%
Other3 · 4%

Clinical Trials

Trial Activity

67 trials

Multi-System Analysis of Opioid Receptor Binding
Recruiting·UUniversity of Pennsylvania·Phase 1·NCT05528848·60 enrolled
Effects of Dronabinol in Opioid Maintained Patients
Recruiting·YYale University·Phase 1·NCT04025359·36 enrolled
Endogenous Opioid Response to Injections
Recruiting·MMiddle Tennessee Research Institute·Phase 4·NCT06666621·33 enrolled
Young Houston Emergency Opioid Engagement System
Recruiting·TThe University of Texas Health Science Center, Houston·Phase 4·NCT04811014·250 enrolled
Cannabidiol After Multi-Trauma for Pain and Opioid Therapy
Recruiting·CCentre Integre Universitaire de Sante et Services Sociaux du Nord de l'ile de Montreal·Phase 2·NCT06448923·225 enrolled
Opioid-Free Orthopaedics
Recruiting·EEmory University·Phase 3·NCT04659317·80 enrolled
Opioid-Sparing and Pain-Reducing Properties of Syntocinon: A Dose-Effect Determination
Recruiting·UUniversity of Florida·Phase 1·NCT04218409·45 enrolled
Evaluating Tetrahydrocannabinol as an Adjunct to Opioid Agonist Therapy
Recruiting·BBC Centre on Substance Use·Phase 2·NCT05985850·24 enrolled
A Brief Values Intervention to Support Veterans in Early Buprenorphine Treatment
Recruiting·VVA Office of Research and Development·Preclinical·NCT05189223·50 enrolled
Stopping Opioid Overuse in Obstetrics to Halt Exposure Trial
Active, not recruiting·UUniversity of Missouri, Kansas City·Phase 4·NCT04680221·97 enrolled
Facilitating Opioid Care Connections: System Level Strategies to Improve Use of Medication-Assisted Treatment (MAT) and Movement Through the Opioid Care Cascade for Defendants in a New Opioid Court System
Active, not recruiting·NNew York State Psychiatric Institute·Preclinical·NCT04216719·3,440 enrolled
Evaluation of the O'Neil Long Acting Naltrexone Implant in Opioid Dependent Persons
Not yet recruiting·GGo Medical Industries Pty Ltd·Phase 2·NCT05382091·250 enrolled
Opioid-Sparing Joint Replacement
Not yet recruiting·EEmory University·Phase 3·NCT07348627·120 enrolled
Evaluation of Switch to Dolutegravir/Lamivudine (DTG/3TC) From Current Suppressive Antiretroviral Therapy in People Living With HIV (PLWH) Receiving Opioid Agonist Therapy (OAT)
Not yet recruiting·SSaskatchewan Health Authority - Regina Area·Phase 4·NCT06580873·40 enrolled
ACL-R Opioid Sparing Study
Enrolling by invitation·CCampbell Clinic·Phase 3·NCT06561035·56 enrolled
Page 1 of 5

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)